Prognostic value of ALP and PSA flare In patients with CRPC who are treated with docetaxel, cabazitaxel, abiraterone or enzalutamide.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22381

Enrollment

1000

Registered

2020-01-23

Start date

2020-01-23

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

None

Eligibility

Inclusion criteria

Inclusion criteria: • diagnosis of metastatic CRPC (mCRPC), and • treatment, current or previous, with one or more of the following agents: docetaxel, cabazitaxel, abiraterone, enzalutamide

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Overall survival (OS): from start of treatment with docetaxel, cabazitaxel, abiraterone or enzalutamide until last follow up or death (whichever comes first). Last follow up or death will be obtained from the subjects medical file. Last follow up is regarded as the most recent follow up contact of the subject.	—

Secondary

Measure	Time frame
• Time to flare • Biochemical progression (progression in PSA according to PCWG3 criteria) • Time to treatment switch All secondary outcomes will be determined from start of treatment, for every treatment separately. In case of several flares each flare will be taken along in the analysis.	—

Contacts

Public ContactNadine Pouw

Franciscus Gasthuis & Vlietland

n.pouw@franciscus.nl0031 10 4616091

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)